Tata Memorial Center develops Rs 100 tablet to prevent resurgence of cancer

The Tata Memorial Centre (TMC) has achieved a significant breakthrough in cancer treatment, developing a ₹100 tablet aimed at reducing chemotherapy side effects and preventing cancer resurgence. 

Dr. Rajendra Badwe, Director of the Tata Memorial Centre, revealed the institute’s success in creating an affordable tablet through its new research. 

The breakthrough comes after a decade-long study by Tata Memorial Hospital (TMH) doctors, uncovering the release of cell-free chromatin particles by dying cancer cells post-chemotherapy and radiotherapy. These particles can transform healthy cells into cancerous ones.

The study identified that a pro-oxidant combination of resveratrol and copper effectively destroyed chromatin, regulating toxicity in chemotherapy patients. This groundbreaking discovery opens new avenues for cancer treatment, focusing on preventing relapse and minimizing treatment side effects. The new tablet is expected to play a crucial role in addressing these challenges. Dr. Badwe emphasized that understanding the metastasis mechanism has been a significant outcome of the research.

While the trials of this innovative treatment are underway, Dr. Badwe cautioned that widespread availability may take a few years. The current studies have shown promising results, leading to the initiation of large-scale patient trials. The institute has approached drug manufacturing companies to produce the formulated drug in pill form. The groundbreaking ₹100 tablet is poised to revolutionize cancer treatment, offering an affordable solution to alleviate side effects and enhance patient outcomes.

Tata Memorial Centre’s breakthrough research addresses the challenges of cancer treatment by developing an affordable tablet to reduce side effects and prevent cancer resurgence.